Better glycemic control seen with basal insulin plus lixisenatide

09/24/2013 | Healio

Diabetes patients who used lixisenatide as an add-on to basal insulin had lower A1C, body weight and self-measured blood glucose profiles than those in the placebo arm, researchers reported at the European Association for the Study of Diabetes meeting. Patients with baseline fasting plasma glucose of less than 6.7 mmol/L showed greater placebo-adjusted improvements compared with those who had higher fasting glucose levels, researchers added.

View Full Article in:

Healio

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ